Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

This study is testing cemiplimab — an immunotherapy drug that helps the immune system fight cancer — as a first-line treatment for people with advanced basal cell carcinoma (BCC), a type of skin cancer. It is for patients whose cancer has spread or cannot be treated with surgery or radiation. **You may be eligible if...** - You are 18 or older with a biopsy-confirmed diagnosis of basal cell carcinoma - Your cancer is locally advanced (spread nearby but not to distant organs) and cannot be surgically removed or treated with radiation - You are in good general health with adequate blood counts and organ function - Your expected survival is at least 6 months **You may NOT be eligible if...** - You have already received prior immunotherapy - You have an active autoimmune disease requiring immune-suppressing medications - You have uncontrolled infections, significant heart disease, or active brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.